Free Trial

Eliem Therapeutics Q2 2024 Earnings Report

Eliem Therapeutics logo
$1.28 +0.01 (+0.79%)
As of 03/28/2025

Eliem Therapeutics EPS Results

Actual EPS
-$1.81
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eliem Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eliem Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Eliem Therapeutics Earnings Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Eliem Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eliem Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eliem Therapeutics and other key companies, straight to your email.

About Eliem Therapeutics

Eliem Therapeutics (NASDAQ:ELYM), a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

View Eliem Therapeutics Profile

More Earnings Resources from MarketBeat